National Cancer Center is leading the new drug development in Japan.

再生ボタン

Our Achievement

200patients
Number of Patients per year
enrolled in phase 1 trials
41
Number of ongoing
Phase 1 trials
15
Number of ongoing FIH
phase 1 trials
75%
Rate of global trials in FIH
phase 1 trials

Phase 1 Trials
Professional Team

Our program shares the vision and brings the state-of-the-art to our patients based on research and the patient-centered patient care with the assurance of the safety.

先端医療科医員 小山隆文
Takafumi Koyama M.D.

Attending Physician, Department of Experimental Therapeutics

先端医療科医長 清水俊雄
Toshio Shimizu M.D., Ph.D.

Head of Physicians, Department of Experimental Therapeutics

先端医療科医員 佐藤潤
Jun Sato M.D., Ph.D.

Attending Physician, Department of Experimental Therapeutics

We accelerate early-phase cancer
drug development

National Cancer Center Hospital plays a crucial role in anti-cancer drug development. Recently, the new drug development has been getting more globalized to keep up with the worldwide trend. Participation in the global First-in-Human trials is pressing issues for us. We aim to accelerate new drug development and deliver more precise new anti-cancer drugs for patients

国立がん研究センター 中央病院 先端医療科のスタッフ一同